| Autor: |
Broutin M; UMR Virologie, INRAE, ANSES, EnvA, 94700 Maisons-Alfort, France.; SEPPIC Paris La Défense, 92250 La Garenne Colombes, France., Costa F; UMR Virologie, INRAE, ANSES, EnvA, 94700 Maisons-Alfort, France., Peltier S; SEPPIC Paris La Défense, 92250 La Garenne Colombes, France., Maye J; SEPPIC Paris La Défense, 92250 La Garenne Colombes, France., Versillé N; SEPPIC Paris La Défense, 92250 La Garenne Colombes, France., Klonjkowski B; UMR Virologie, INRAE, ANSES, EnvA, 94700 Maisons-Alfort, France. |
| Abstrakt: |
There is a significant need for highly effective vaccines against emerging and common veterinary infectious diseases. Canine adenovirus type 2 (CAV2) vectors allow rapid development of multiple vaccines and have demonstrated their potential in animal models. In this study, we compared the immunogenicity of a non-replicating CAV2 vector encoding the rabies virus glycoprotein with and without Montanide TM ISA 201 VG, an oil-based adjuvant. All vaccinated mice rapidly achieved rabies seroconversion, which was associated with complete vaccine protection. The adjuvant increased rabies antibody titers without any significant effect on the anti-CAV2 serological responses. An RT 2 Profiler™ PCR array was conducted to identify host antiviral genes modulated in the blood samples 24 h after vaccination. Functional analysis of differentially expressed genes revealed the up-regulation of the RIG-I, TLRs, NLRs, and IFNs signaling pathways. These results demonstrate that a water-in-oil-in-water adjuvant can shape the immune responses to an antigen encoded by an adenovirus, thereby enhancing the protection conferred by live recombinant vaccines. The characterization of early vaccine responses provides a better understanding of the mechanisms underlying the efficacy of CAV2-vectored vaccines. |
